WillingMed has independently developed and successfully reported and approved a series of automated testing instruments, software, testing reagents and other IVD products, and obtained intellectual property rights for more than 40 core technologies.
WillingMed (Chinese: 微岩医学) has completed a Series B financing round of several hundred million RMB. This round was jointly invested by Galaxy Innovation Capital, Haier Capital and Hunan Medicine Development Private Equity Fund. The funds raised in this round will mainly be used to accelerate the implementation of the strategic layout of medical device product registration and certification, new product development and the construction of the "pathogenic microbial skynet laboratory".
Founded in 2019, WillingMed Technology (Beijing) Co., Ltd. will focus on precision diagnosis of clinical infections and promote the integration of artificial intelligence (AI) and macro-genome high-throughput sequencing (mNGS). Based on the three cutting-edge technology lines of high-throughput sequencing (NGS), microfluidic chip and transcriptome sequencing, WillingMed has independently developed and successfully reported and approved a series of automated testing instruments, software, testing reagents and other IVD products, and obtained intellectual property rights for more than 40 core technologies.
At present, the company has served more than 1,500 clinical hospitals and established strategic and project partnerships with institutions such as the Institute of Microbiology of the Chinese Academy of Sciences, Peking Union Medical College Hospital, Peking University People's Hospital, China-Japan Friendship Hospital and Guangzhou Institute of Respiratory Health.
Up to now, in addition to the mNGS class IVD registered products, WillingMed has also landed a local automation landing solution, realizing a multi-level layout of equipment + reagents + software to prepare for the mNGS project to be routinely carried out in the laboratory department in the future. Currently, the solution has been applied in more than twenty tertiary hospitals, allowing mNGS technology to benefit a wider range of people in the clinical end in the future.
In the second half of 2021, the company also completed the fully independent development of PathoReport® automated intelligent reporting system, according to reports, it can be compatible with the hospital HIS system can achieve the automation of the entire reporting process, intelligent, without the need to equip raw letter staff, "only a server, in 30 minutes That is, 30 test samples can be completed in one click to generate reports".
These two systems, together with WillingMed's own kits and sequencers, provide WillingMed with a complete localization solution for mNGS. Next, WillingMed will also join hands with its industrial shareholder, Runda Medical, to form an exclusive distribution network barrier through its nationwide channel resources, focus on pathogenic microbial testing based on WillingMed's fully automated mNGS solutions, and jointly promote the construction of a platform for precision diagnosis and treatment of infectious/contagious diseases.
In addition, the company plans to cooperate with Runda, chain ICL, hospital precision center and hospital laboratory department to build more than 100 delivery centers and complete the industrial layout within three years, so as to realize the rapid detection of complex infections for macro-genome high-throughput sequencing (mNGS) technology and form a new pattern of pathogenic microorganism skynet laboratory.